A61K 47/6897
Pre-targeting systems with two or three steps using antibody conjugates
Official title: {Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}
A61K47/6897 (Pre-targeting systems with two or three steps using antibody conjugates) appears on 294 US grants and 350 published applications in this corpus.
Search patents in A61K- Granted patents
- 294
- Published applications
- 350
- Assignees
- 172
- Inventors
- 586
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 7 | 0 |
| 1997 | 12 | 0 |
| 1998 | 9 | 0 |
| 1999 | 11 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 3 |
| 2002 | 9 | 12 |
| 2003 | 6 | 18 |
| 2004 | 2 | 13 |
| 2005 | 8 | 15 |
| 2006 | 7 | 18 |
| 2007 | 5 | 9 |
| 2008 | 4 | 12 |
| 2009 | 14 | 20 |
| 2010 | 11 | 12 |
| 2011 | 12 | 12 |
| 2012 | 9 | 22 |
| 2013 | 20 | 15 |
| 2014 | 13 | 19 |
| 2015 | 13 | 14 |
| 2016 | 13 | 22 |
| 2017 | 13 | 14 |
| 2018 | 9 | 7 |
| 2019 | 12 | 17 |
| 2020 | 6 | 16 |
| 2021 | 12 | 14 |
| 2022 | 7 | 9 |
| 2023 | 9 | 14 |
| 2024 | 10 | 14 |
| 2025 | 3 | 5 |
| 2026 | 5 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Radioligands for pretargeted PET imaging and methods of their therapeutic use15 Sep 2026US 12,734,258 B2Memorial Sloan Kettering Cancer Center
- Chemically cleavable group15 Sep 2026US 12,735,444 B2Tagworks Pharmaceuticals B.V.
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates7 Apr 2026US 12,594,341 B2
- Cardiac troponin I specific antibody, kit and uses thereof31 Mar 2026US 12,590,144 B2Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies13 Aug 2026US 2026/0232834 A1GlaxoSmithKline Intellectual Property Development Limited
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates16 Jul 2026US 2026/0199506 A1
- Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof23 Apr 2026US 2026/0109765 A1
- Novel copolymer19 Feb 2026US 2026/0048140 A1Kowa Company, Ltd.
- Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy13 Nov 2025US 2025/0345466 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents
- Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments180US 5,716,595 AImmunomedics, Inc. · 1998
- Targeted combination immunotherapy of cancer175US 6,077,499 AImmunomedics, Inc. · 2000
- Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy173US 6,096,289 AImmunomedics, Inc. · 2000
- Interactive molecular conjugates150US 5,998,588 AUniversity of Washington · 1999
- Multivalent immunoglobulin-based bioactive assemblies139US 7,527,787 B2IBC Pharmaceuticals, Inc. · 2009